Lyra Therapeutics, Inc.
LYRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2 | $2 | $1 | $0 |
| % Growth | -1.5% | 14.3% | 378.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $30 |
| Gross Profit | $2 | $2 | $1 | -$29 |
| % Margin | 100% | 100% | 100% | -10,318.9% |
| R&D Expenses | $44 | $48 | $39 | $30 |
| G&A Expenses | $19 | $19 | $18 | $14 |
| SG&A Expenses | $19 | $19 | $18 | $14 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $36 | $2 | $1 | -$30 |
| Operating Expenses | $98 | $69 | $58 | $14 |
| Operating Income | -$96 | -$67 | -$56 | -$44 |
| % Margin | -6,280.8% | -4,308.1% | -4,131% | -15,303.5% |
| Other Income/Exp. Net | $3 | $4 | $1 | $0 |
| Pre-Tax Income | -$93 | -$63 | -$55 | -$44 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$93 | -$63 | -$55 | -$44 |
| % Margin | -6,090.9% | -4,023.1% | -4,055.6% | -15,267.7% |
| EPS | -1.43 | -1.26 | -1.83 | -3.35 |
| % Growth | -13.5% | 31.1% | 45.4% | – |
| EPS Diluted | -1.43 | -1.26 | -1.83 | -3.35 |
| Weighted Avg Shares Out | 65 | 50 | 30 | 13 |
| Weighted Avg Shares Out Dil | 65 | 50 | 30 | 13 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $4 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $1 | $1 |
| EBITDA | -$60 | -$65 | -$54 | -$43 |
| % Margin | -3,928.4% | -4,188.1% | -3,956.2% | -14,952.3% |